Latest Administration News

Page 7 of 248
Marine Biomedical has secured US FDA 510(k) clearance for PearlBone, giving Orthocell a clearer path into bone regeneration through its 12% strategic stake and distribution rights. The commercial opportunity is advancing, but revenue, launch timing and definitive distribution arrangements remain undisclosed.
Ada Torres
Ada Torres
3 Nov 2026
Clorox delivered a sharp first-quarter rebound, helped by the GOJO acquisition and an easier comparison after last year’s ERP-related inventory drawdown. But rising commodity, manufacturing and logistics costs have pushed its full-year margin assumptions lower, with adjusted earnings now expected nearer the bottom of the unchanged range.
Victor Sage
Victor Sage
3 Nov 2026
Williams delivered higher third-quarter earnings and cash generation while keeping its 2026 guidance intact. The Momentum Midstream acquisition and a growing slate of pipeline, storage and power projects are now central to the company’s expansion case.
Maxwell Dee
Maxwell Dee
3 Nov 2026
Vertex has raised its full-year 2026 revenue guidance after third-quarter sales climbed 12%, but the Crinetics acquisition sharply increased costs and debt. The next major test arrives on 30 November, when US regulators are due to rule on povetacicept for IgA nephropathy.
Ada Torres
Ada Torres
3 Nov 2026
CAQ Holdings ended the September quarter with $487,000 in cash and an estimated 1.34 quarters of funding, while all $3.957 million of its financing facilities remained drawn. Property revenue was stable, but the company said its proposed debt extension had not been finalised.
Eva Park
Eva Park
2 Nov 2026
The FDA has granted orphan drug designation to Neuren’s NNZ-2591 for neonatal hypoxic-ischemic encephalopathy, giving the programme potential US exclusivity and regulatory fee relief. The company is completing a juvenile animal safety study before targeting an IND submission in the first half of 2027.
Victor Sage
Victor Sage
2 Nov 2026
Nexsen has secured ISO 13485 certification covering the design, development and manufacture of its StrepSure Group B Streptococcus diagnostic. The milestone strengthens the product’s regulatory and manufacturing platform, but does not yet amount to FDA or TGA approval.
Ada Torres
Ada Torres
2 Nov 2026
ResMed has delivered a stronger first quarter for fiscal 2027, with revenue up 6% to US$1.415 billion and net income rising 20% to US$418 million. The headline result was helped by a preliminary gain on the MatrixCare sale, while the core Sleep and Breathing Health business continued to expand.
Ada Torres
Ada Torres
2 Nov 2026
Nodestream has completed its $6.5 million placement, launched Missions and expanded its defence push across the US and Europe. But revenue remains under pressure, quarterly cash burn is substantial and auditors have warned of material uncertainty over the company’s ability to continue as a going concern.
Sophie Babbage
Sophie Babbage
2 Nov 2026
European Metals says a single tunnel kiln could cut Cinovec’s capital cost by about US$112 million and operating costs by US$10 million a year, but the savings remain preliminary. The company also has until 13 November to secure EUR6.448 million if it wants to restore its 49% stake in the project vehicle.
Maxwell Dee
Maxwell Dee
30 Oct 2026
ARC Funds has acquired a 3% stake in Ausbiz Wealth using proceeds from a $250,000 share placement, but ended September with just $265,000 in cash and no undrawn facilities. The company says it plans to raise further capital while an $800,000 related-party loan matures on 31 December.
Claire Turing
Claire Turing
30 Oct 2026
Zuleika Gold will resume its exploration-led strategy after CZR Resources formally withdrew its all-scrip takeover offer. The company ended September debt-free with $42.1 million in cash and liquid assets, while assays and several drilling programmes remain ahead.
Maxwell Dee
Maxwell Dee
30 Oct 2026

Browse the archive

Full archive